AMPE:NYE-Ampio Pharm (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.06

Change

-0.01 (-8.57)%

Market Cap

USD 0.01B

Volume

3.84M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AMPE Stock Forecast & Price:
Based on the Ampio Pharm stock forecasts from 0 analysts, the average analyst target price for Ampio Pharm is not available over the next 12 months. Ampio Pharm’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Ampio Pharm is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Ampio Pharm’s stock price was USD 0.06. Ampio Pharm’s stock price has changed by -20.00% over the past week, -30.43% over the past month and -96.38% over the last year.

No recent analyst target price found for Ampio Pharm
No recent average analyst rating found for Ampio Pharm

About Ampio Pharm (AMPE:NYE)

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinica ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.62 (+0.65%)

USD215.92B 32.65 3.02
BHVN Biohaven Pharmaceutical Holdin..

+0.23 (+0.15%)

USD10.90B N/A -15.30
DNA Ginkgo Bioworks Holdings

+0.09 (+3.21%)

USD5.25B N/A -1.31
RCUS Arcus Biosciences Inc

+1.37 (+5.59%)

USD1.82B 25.21 10.11
MYOV Myovant Sciences Ltd

+0.73 (+4.42%)

USD1.61B N/A -11.99
NUVB Nuvation Bio Inc

+0.09 (+4.33%)

USD0.45B N/A 2.22
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
ADCT Adc Therapeutics SA

+0.16 (+3.43%)

USD0.36B -99,999.99 -0.65
ZYME Zymeworks Inc

+0.24 (+4.55%)

USD0.32B 300.20 -0.50
LCTX Lineage Cell Therapeutics Inc

N/A

USD0.20B 3.63 -2.90

ETFs Containing AMPE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -88.77% 6% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.77% 6% F 1% F
Trailing 12 Months  
Capital Gain -96.21% 3% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.21% 3% F N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 42.33% 82% B- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.33% 82% B- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 107.09% 12% F 6% F
Risk Adjusted Return 39.52% 85% B 62% D-
Market Capitalization 0.01B 17% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.87 31% F 22% F
Price/Book Ratio 0.85 69% D+ 76% C
Price / Cash Flow Ratio -1.06 22% F 76% C
EV/EBITDA 0.21 28% F 75% C
Management Effectiveness  
Return on Equity -86.80% 41% F 5% F
Return on Invested Capital -91.84% 36% F 4% F
Return on Assets -58.04% 17% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.35 83% B 65% D
Short Percent 5.34% 31% F 39% F
Beta 1.75 16% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.